E-mail  
Home
 
AboutUs
 
Service
 
Products
 
Order Information
 
Contact us
Insert title here
Featured Products
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10012  |  AZD-5438
HY-10014  |  R547
HY-10032  |  PF 477736
HY-10087  |  Navitoclax
HY-10128  |  ZM-447439
HY-10161  |  Tozasertib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10228  |  Motesanib
HY-10249  |  GSK-690693
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10992  |  AZD-7762
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-11009  |  CGP60474
more    
Products
-->
HY-10087

CAS:923564-51-6

 (Synonyms  ABT-263;ABT 263;ABT263)
923564-51-6  Technical Data: Price and Availability of  Cas No:923564-51-6

Cas : 923564-51-6 M.Wt: 974.61
Cas : 923564-51-6 Formula: C47H55ClF3N5O6S3
Cas : 923564-51-6 Purity: >98 %
Cas : 923564-51-6 Storage: at 20℃ 2 years
Cas : 923564-51-6 Solubility: 10 mM in DMSO
Cas : 923564-51-6 Name: Navitoclax
USD
5mg/$50 In-stock
10mg/$80 In-stock
25mg/$140 In-stock
50mg/$200 In-stock
100mg/$350 In-stock
1g Get quote
5g Get quote
>10g Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please
inquire via sales@chemexpress.cn
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Online Inquiry
 
923564-51-6  Data Sheet:
 
Introduction of 923564-51-6 :
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM. IC50 Value: ≤ 0.5 nM(Ki for Bcl-xL); ≤1 nM(Ki for Bcl-2); ≤1 nM(Ki for Bcl-w) Target: Bcl-2 Family in vitro: ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. in vivo: ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens.
 
References on 923564-51-6 :
 

Keywords: buy Navitoclax | Navitoclax Supplier | purchase Navitoclax | Navitoclax cost | Navitoclax manufacturer | order Navitoclax | Navitoclax distributor | Navitoclax structure
buy 923564-51-6 | 923564-51-6 Supplier | purchase 923564-51-6 | 923564-51-6 cost | 923564-51-6 manufacturer | order 923564-51-6 | 923564-51-6 distributor | 923564-51-6 structure
Insert title here
 
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
TEL:
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn